Table 1.
Cohort characteristics
| # | PM delay (h:min) | Pathological diagnosis (mutation) | Sex | Age | Braak | Amyloid |
|---|---|---|---|---|---|---|
| 1 | 6:35 | Control | F | 92 | III | 0 |
| 2 | 7:10 | Control | F | 78 | I | A |
| 3 | 4:35 | Control | F | 78 | II | A |
| 4 | 7:15 | Control | M | 95 | II | B |
| 5 | 5:15 | Control | M | 83 | I | A |
| 6 | 5:00 | EOAD | M | 61 | VI | C |
| 7 | 5:05 | EOAD | M | 59 | VI | C |
| 8 | 4:40 | EOAD | M | 62 | V | B |
| 9 | 4:45 | EOAD | M | 64 | V | C |
| 10 | 5:15 | EOAD | M | 62 | VI | C |
| 11 | 5:30 | LOAD | M | 88 | VI | C |
| 12 | 7:00 | LOAD | F | 92 | V | C |
| 13 | 4:40 | LOAD | F | 89 | V | C |
| 14 | 6:25 | LOAD | F | 91 | IV | C |
| 15 | 3:05 | LOAD | M | 74 | VI | C |
| 16 | 6:05 | CAA type 1 | M | 68 | II | C |
| 17 | 4:20 | CAA type 1 | M | 81 | V | C |
| 18 | 4:20 | CAA type 1 | F | 96 | V | C |
| 19 | 3:25 | CAA type 1 | M | 94 | V | C |
| 20 | 6:00 | CAA type 1 | F | 75 | V | C |
| 21 | 5:30 | PART | F | 81 | II | 0 |
| 22 | 3:52 | PART | F | 89 | III | 0 |
| 23 | 5:00 | PART | F | 87 | II | 0 |
| 24 | 5:50 | PART | F | 93 | II | 0 |
| 25 | 6:35 | PART | F | 103 | IV | 0 |
| 26 | 3:35 | FTLD-TDP (Progranulin) | F | 76 | n.a. | A |
| 27 | 5:23 | FTLD-Tau (P301L) | M | 60 | n.a. | 0 |
| 28 | 6:25 | FTLD-Tau (P301L) | M | 64 | n.a. | 0 |
| 29 | 6:15 | FTLD-Tau (PiD) | M | 60 | n.a. | 0 |
| 30 | 24:00 | PD | M | 57 | I | 0 |
| 31 | 33:00 | LBD/AD | F | 78 | VI | B |
| 32 | 14:00 | PD | M | 68 | I | 0 |
Abbreviations: CAA type 1 capillary cerebral amyloid angiopathy type 1, EOAD early onset Alzheimer’s disease, FTLD-tau frontotemporal lobar degeneration with tau pathology, FTLD-TDP-43 frontotemporal lobar degeneration with TDP-43 pathology, LOAD late onset Alzheimer’s disease, n.a. not applicable, PART primary age-related tauopathy, PiD Pick’s disease, PM delay post-mortem delay and PD Parkinson’s disease